We have identified CTX-M group 1 β-lactamases in 87% of community-acquired Escherichia coli isolates that produce extended-spectrum β-lactamases, with the majority harboring CTX-M-15 and representing the ST131 clonal group. Seventy percent of CTX-M-bearing isolates were from urine specimens; a large proportion was nonsusceptible to levofloxacin, trimethoprim/sulfamethoxazole, and β-lactam antimicrobials. Many patients were relatively youthful (41% ≤65 years old; youngest, age 32). Patients with symptomatic bacteriuria received drugs to which the organisms were susceptible, and most had favorable outcomes. Timely recognition of such isolates could help physicians choose more appropriate antibacterial therapy.
|Original language||English (US)|
|Number of pages||5|
|Journal||Diagnostic Microbiology and Infectious Disease|
|State||Published - Mar 2012|
Bibliographical noteFunding Information:
The study was supported by the BMA Medical Foundation and Lang Research, New York Hospital Queens . This material is also based upon work supported by Office of Research and Development, Medical Research Service, Department of Veterans Affairs (J.R.J.).
Copyright 2012 Elsevier B.V., All rights reserved.
- Antimicrobial resistance
- CTX-M-15 β-Lactamase
- Community acquired
- Escherichia coli infections